Angiodynamics (ANGO) Current Deferred Revenue (2012 - 2014)

Angiodynamics' (ANGO) quarterly Current Deferred Revenue came in at $1.5 million in Q1 2014, down 8.97% on a QoQ basis from $1.6 million in Q4 2013.

Angiodynamics (ANGO) Current Deferred Revenue (2012 - 2014) Analysis & Trends

Angiodynamics (ANGO) has 3 years of Current Deferred Revenue data on file, last reported at $1.5 million in Q1 2014.

Quarterly Current Deferred Revenue changed N/A year-over-year to $1.5 million in Q1 2014, while the trailing twelve-month figure through Feb 2014 was $1.5 million (changed N/A YoY) and the FY2013 annual result came in at $1.6 million, down 49.87% from the prior year.
Current Deferred Revenue slipped to $1.5 million in Q1 2014, from $1.6 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $3.3 million in Q3 2012 to a low of $1.5 million in Q1 2014.
A 3-year average of $2.1 million and a median of $1.6 million in 2013 frame the typical range for Current Deferred Revenue.
The widest YoY moves for Current Deferred Revenue: up 49.87% in 2013, down 52.41% in 2013.
Tracing ANGO's Current Deferred Revenue over 3 years: stood at $3.3 million in 2012, then slumped by 51.63% to $1.6 million in 2013, then declined by 8.97% to $1.5 million in 2014.
The last three Current Deferred Revenue figures came in at $1.5 million (Q1 2014), $1.6 million (Q4 2013), and $1.6 million (Q3 2013), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn
10	Angiodynamics	658.19 Mn	604.32 Mn	46.77 Mn

Download Data